Analyst Ratings For CymaBay Therapeutics (NASDAQ:CBAY)
Today, Roth Capital initiated coverage on CymaBay Therapeutics (NASDAQ:CBAY) with a Buy with a price target of $27.00.
Some recent analyst ratings include
- 1/25/2018-Roth Capital initiated coverage with a Buy rating.
- 1/24/2018-HC Wainwright Reiterated Rating of Buy .
- 11/28/2017-Leerink Swann Reiterated Rating of Buy.
- 11/8/2017-Cantor Fitzgerald Reiterated Rating of Buy.
- 10/27/2017-Piper Jaffray Companies Reiterated Rating of Buy.
- 8/18/2017-SunTrust Banks initiated coverage with a Buy rating.
Recent Insider Trading Activity For CymaBay Therapeutics (NASDAQ:CBAY)
CymaBay Therapeutics (NASDAQ:CBAY) has insider ownership of 15.10% and institutional ownership of 69.12%.
- On 1/22/2018 Kurt Von Emster, Director, sold 138,253 with an average share price of $10.40 per share and the total transaction amounting to $1,437,831.20.
- On 1/19/2018 Kurt Von Emster, Director, sold 144,216 with an average share price of $10.25 per share and the total transaction amounting to $1,478,214.00.
- On 1/5/2018 Kurt Von Emster, Director, sold 4,300 with an average share price of $10.21 per share and the total transaction amounting to $43,903.00.
- On 12/22/2017 Kurt Von Emster, Director, sold 173,192 with an average share price of $9.41 per share and the total transaction amounting to $1,629,736.72.
- On 11/10/2017 Kurt Von Emster, Director, sold 50,048 with an average share price of $9.26 per share and the total transaction amounting to $463,444.48.
- On 11/2/2017 Carl Goldfischer, Director, sold 18,000 with an average share price of $8.66 per share and the total transaction amounting to $155,880.00.
- On 11/2/2017 Charles Mcwherter, SVP, bought 5,000 with an average share price of $8.67 per share and the total transaction amounting to $43,350.00.
Recent Trading Activity for CymaBay Therapeutics (NASDAQ:CBAY)
Shares of CymaBay Therapeutics closed the previous trading session at 11.90 up +0.21 1.78% with 777053 shares trading hands.
